250 related articles for article (PubMed ID: 18455395)
21. Prescribing extended adjuvant letrozole.
Gelmon K
Breast; 2007 Oct; 16(5):446-55. PubMed ID: 17544670
[TBL] [Abstract][Full Text] [Related]
22. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Dixon JM
Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
[TBL] [Abstract][Full Text] [Related]
23. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Sagara Y; Kosha S; Baba S; Dokiya F; Tamada S; Sagara Y; Matsuyama Y; Ohi Y; Ando M; Rai Y; Sagara Y; Douchi T
Breast Cancer; 2010 Jul; 17(3):212-7. PubMed ID: 19526308
[TBL] [Abstract][Full Text] [Related]
24. Menopausal symptoms and adjuvant therapy-associated adverse events.
Hadji P
Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
[TBL] [Abstract][Full Text] [Related]
25. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Ingle JN
Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
[TBL] [Abstract][Full Text] [Related]
26. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Sestak I; Sapunar F; Cuzick J
J Clin Oncol; 2009 Oct; 27(30):4961-5. PubMed ID: 19752338
[TBL] [Abstract][Full Text] [Related]
27. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
28. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Mamounas EP
Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?
Monnier A
Cancer Treat Rev; 2006 Nov; 32(7):532-40. PubMed ID: 16978789
[TBL] [Abstract][Full Text] [Related]
30. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
31. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Laroche M; Borg S; Lassoued S; De Lafontan B; Roché H
J Rheumatol; 2007 Nov; 34(11):2259-63. PubMed ID: 17937464
[TBL] [Abstract][Full Text] [Related]
32. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
[TBL] [Abstract][Full Text] [Related]
33. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
Burdette-Radoux S; Muss HB
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S37-41. PubMed ID: 19561005
[TBL] [Abstract][Full Text] [Related]
34. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
35. Aromatase inhibitors in the management of early breast cancer.
Nabholtz JM
Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
[TBL] [Abstract][Full Text] [Related]
36. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
37. Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Needleman SJ; Tobias JS
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1871-81. PubMed ID: 19046107
[TBL] [Abstract][Full Text] [Related]
38. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Din OS; Dodwell D; Wakefield RJ; Coleman RE
Breast Cancer Res Treat; 2010 Apr; 120(3):525-38. PubMed ID: 20157776
[TBL] [Abstract][Full Text] [Related]
39. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Snoj N; Paridaens R; Cufer T
Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
[TBL] [Abstract][Full Text] [Related]
40. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
